Details of Disease

General Information of Disease (ID: DISOKN4Y)

• Disease Name: Gastric neoplasm
• Synonyms: gastric tumor; gastric neoplasm; tumor of stomach; stomach tumor; neoplasm of the stomach; tumor of the stomach; tumour of stomach; stomach neoplasm; neoplasm of stomach; stomach neoplasm (disease); gastric tumour; stomach tumour; tumour of the stomach
• Definition: A benign or malignant neoplasm involving the stomach.
• Disease Hierarchy:
  DISTBY9Z: Tumour
  DISJLJZ9: Stomach disease
  DISPOJCT: Digestive system neoplasm
  DISOKN4Y: Gastric neoplasm
• Disease Identifiers:
  MONDO ID: MONDO_0021085
  MESH ID: D013274
  UMLS CUI: C0038356
  MedGen ID: 20958
  HPO ID: HP:0006753
  SNOMED CT ID: 126824007

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 207 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADRB1	TTR6W5O	Limited	Biomarker	[1]
ADRB2	TTG8ZWP	Limited	Biomarker	[1]
ANXA5	TT2Z83I	Limited	Biomarker	[2]
AREG	TT76B3W	Limited	Therapeutic	[2]
BDNF	TTSMLOH	Limited	Biomarker	[2]
BMP7	TTKOBRA	Limited	Biomarker	[2]
BRAF	TT0EOB8	Limited	Biomarker	[3]
CASP8	TT6SZNG	Limited	Biomarker	[4]
CDC25C	TTESBNC	Limited	Genetic Variation	[5]
CDKN2A	TTFTWQ8	Limited	Posttranslational Modification	[6]
CTSL	TT36ETB	Limited	Biomarker	[2]
DNMT1	TT6S2FE	Limited	Biomarker	[7]
DNMT3B	TT6VZ78	Limited	Biomarker	[7]
DPYD	TTZPS91	Limited	Altered Expression	[8]
EBI3	TTJF68X	Limited	Biomarker	[2]
F2R	TTL935N	Limited	Biomarker	[2]
FST	TTDNM9W	Limited	Biomarker	[2]
FYN	TT2B9KF	Limited	Biomarker	[2]
GREM1	TTOUZN5	Limited	Biomarker	[2]
HBEGF	TT15SL0	Limited	Therapeutic	[9]
HMOX1	TTI6V2A	Limited	Biomarker	[10]
IGFBP3	TTZHNQA	Limited	Genetic Variation	[11]
IGFBP7	TTUQ01B	Limited	Biomarker	[2]
IRS2	TTF95B8	Limited	Biomarker	[2]
JUN	TTS7IR5	Limited	Altered Expression	[12]
KISS1R	TT3KBZY	Limited	Biomarker	[2]
KIT	TTX41N9	Limited	Biomarker	[13]
KRAS	TTM8FR7	Limited	Genetic Variation	[14]
MAPK3	TT1MG9E	Limited	Altered Expression	[12]
MYC	TTNQ5ZP	Limited	Biomarker	[15]
NOS3	TTCM4B3	Limited	Biomarker	[2]
NT5E	TTK0O6Y	Limited	Biomarker	[2]
PRKCB	TTYPXQF	Limited	Biomarker	[1]
PSCA	TT9T4AV	Limited	Biomarker	[16]
RBP4	TT0C8BY	Limited	Biomarker	[2]
REG4	TTVZEHU	Limited	Biomarker	[17]
RGS2	TTKB7T3	Limited	Biomarker	[2]
RHOA	TTP2U16	Limited	Biomarker	[18]
RORA	TT1TYN7	Limited	Biomarker	[2]
SDHD	TTVH9W8	Limited	Biomarker	[19]
SERPINE1	TTTO43N	Limited	Altered Expression	[20]
TFF1	TTNOJIZ	Limited	Biomarker	[21]
THBD	TTAPV67	Limited	Biomarker	[2]
UMPS	TTAFJUD	Limited	Altered Expression	[22]
CASP2	TT12VNG	Disputed	Altered Expression	[23]
CASP7	TTM7Y45	Disputed	Altered Expression	[23]
CDC20	TTBKFDV	Disputed	Altered Expression	[24]
KLK6	TTLPF4X	Disputed	Altered Expression	[25]
RBPJ	TT72D4Z	Disputed	Altered Expression	[26]
TUBB2A	TTJ2PTI	Disputed	Genetic Variation	[27]
AHR	TT037IE	moderate	Altered Expression	[28]
AURKA	TTPS3C0	moderate	Biomarker	[29]
BAP1	TT47RXJ	moderate	Biomarker	[30]
BCL2L1	TTRE6AX	moderate	Therapeutic	[31]
BIRC2	TTQ5LRD	moderate	Altered Expression	[32]
CASP6	TTKW4ML	moderate	Altered Expression	[33]
CAV1	TTXUBN2	moderate	Altered Expression	[34]
CCKBR	TTVFO0U	moderate	Posttranslational Modification	[35]
CDH2	TT1WS0T	moderate	Biomarker	[36]
CDK4	TT0PG8F	moderate	Biomarker	[37]
CDKN1B	TTLGFVW	moderate	Biomarker	[38]
EPHB6	TTZEMUY	moderate	Biomarker	[39]
ERBB2	TTR5TV4	moderate	Biomarker	[40]
ERBB3	TTSINU2	moderate	Genetic Variation	[41]
FHIT	TTMS54D	moderate	Biomarker	[42]
GAST	TT4LRVO	moderate	Biomarker	[43]
GSTP1	TT40K12	moderate	Biomarker	[44]
LGALS3	TTFPQV7	moderate	Altered Expression	[45]
MLH1	TTISG27	moderate	Altered Expression	[46]
MTA1	TTO4HUS	moderate	Altered Expression	[47]
MTHFR	TTQWOU1	moderate	Genetic Variation	[48]
MUC1	TTBHFYQ	moderate	Biomarker	[49]
MUC5AC	TTEL90S	moderate	Biomarker	[50]
NPM1	TTHBS98	moderate	Altered Expression	[51]
NR4A1	TTMXE2Q	moderate	Biomarker	[52]
PGC	TT7K6AD	moderate	Genetic Variation	[53]
PHB	TT6U071	moderate	Biomarker	[44]
PLAU	TTGY7WI	moderate	Altered Expression	[54]
PLAUR	TTNOSTX	moderate	Altered Expression	[55]
PPARG	TTT2SVW	moderate	Biomarker	[56]
PTGS2	TTVKILB	moderate	Biomarker	[57]
RPL15	TTQRVC9	moderate	Biomarker	[44]
RUNX3	TTKCVO7	moderate	Biomarker	[58]
SERPINB5	TT1KW50	moderate	Altered Expression	[59]
SHH	TTIENCJ	moderate	Biomarker	[60]
SLC16A3	TTG6VD5	moderate	Biomarker	[61]
STAT3	TTHJT3X	moderate	Altered Expression	[62]
TYMP	TTO0IB8	moderate	Biomarker	[63]
AFP	TTCFEA1	Strong	Biomarker	[64]
AGTR2	TTQVOEI	Strong	Biomarker	[65]
AKR1C3	TT5ZWB6	Strong	Biomarker	[66]
ALB	TTFNGC9	Strong	Biomarker	[66]
ANXA1	TTUCK4B	Strong	Biomarker	[67]
APEX1	TTHGL48	Strong	Biomarker	[44]
APOA1	TT5S8DR	Strong	Biomarker	[66]
ATM	TTKBM7V	Strong	Biomarker	[16]
AURKB	TT9RTBL	Strong	Biomarker	[68]
BDKRB1	TTG5QIA	Strong	Altered Expression	[69]
BDKRB2	TTGY8IW	Strong	Altered Expression	[69]
BIRC5	TTTPU1G	Strong	Altered Expression	[70]
BMP2	TTP3IGX	Strong	Biomarker	[71]
CA1	TTHQPL7	Strong	Biomarker	[66]
CA2	TTANPDJ	Strong	Biomarker	[72]
CD44	TTWFBT7	Strong	Biomarker	[73]
CD9	TTZEIBV	Strong	Altered Expression	[74]
CDCA8	TT04YCM	Strong	Altered Expression	[75]
CDH1	TTLAWO6	Strong	Genetic Variation	[76]
CDKN1A	TT9GUW0	Strong	Altered Expression	[77]
CHEK2	TT9ABMF	Strong	Biomarker	[44]
CLCN3	TT8XNZ7	Strong	Biomarker	[44]
CLDN4	TTMTS9H	Strong	Altered Expression	[78]
CLN3	TTORF9W	Strong	Biomarker	[44]
CTSC	TT4H0V2	Strong	Biomarker	[44]
CYP2A6	TTAQ6ZW	Strong	Biomarker	[79]
FGFR2	TTGJVQM	Strong	Biomarker	[80]
FGG	TTR31L7	Strong	Biomarker	[66]
FOLR1	TTVC37M	Strong	Genetic Variation	[81]
GHRL	TT1OCL0	Strong	Biomarker	[82]
HPSE	TTR7GJO	Strong	Genetic Variation	[83]
HRAS	TT28ZON	Strong	Biomarker	[84]
HRH4	TTXJ178	Strong	Biomarker	[85]
HSD17B2	TT0PT1R	Strong	Altered Expression	[86]
HSPA8	TTMQL3K	Strong	Biomarker	[72]
HSPB1	TT9AZWY	Strong	Biomarker	[66]
HSPD1	TT9HL5R	Strong	Biomarker	[66]
HTR1A	TTSQIFT	Strong	Therapeutic	[87]
IFNGR2	TT13TL0	Strong	Genetic Variation	[88]
IL1RN	TT6GSR3	Strong	Genetic Variation	[89]
IL32	TTD4G7L	Strong	Biomarker	[90]
IMP3	TTEJA2R	Strong	Altered Expression	[91]
ITGA5	TTHIZP9	Strong	Biomarker	[92]
ITGA8	TT1FW8B	Strong	Biomarker	[92]
KCNA5	TTW0CMT	Strong	Altered Expression	[93]
KCNH1	TT9XKUC	Strong	Altered Expression	[94]
KISS1	TTU2O6T	Strong	Biomarker	[2]
KMT2A	TT1GNDM	Strong	Biomarker	[95]
KRT19	TT3JF9E	Strong	Biomarker	[96]
LAPTM4B	TTEJQT0	Strong	Genetic Variation	[97]
M6PR	TT95ICL	Strong	Biomarker	[44]
MAGEA1	TT63M7Q	Strong	Altered Expression	[98]
MAPK1	TT4TQBX	Strong	Altered Expression	[12]
MAPK8	TT0K6EO	Strong	Biomarker	[99]
MET	TTNDSF4	Strong	Altered Expression	[100]
MIA	TT5HNVS	Strong	Biomarker	[2]
MMP10	TTXLEG7	Strong	Biomarker	[101]
MMP7	TTMTWOS	Strong	Biomarker	[102]
MSH2	TTCAWRT	Strong	Altered Expression	[46]
MSLN	TT4RXME	Strong	Biomarker	[103]
MUTYH	TTNB0ZK	Strong	CausalMutation	[104]
NGFR	TTEDJN4	Strong	Altered Expression	[105]
NOTCH2	TT82FVD	Strong	Biomarker	[106]
NPR1	TTM9IYA	Strong	Altered Expression	[107]
NRAS	TTW2R9X	Strong	Genetic Variation	[108]
PDGFRA	TT8FYO9	Strong	Genetic Variation	[109]
PFKFB2	TTQYVKD	Strong	Altered Expression	[110]
PIK3CA	TTEUNMR	Strong	Genetic Variation	[111]
PINX1	TT4FJ3A	Strong	Altered Expression	[112]
PLA2G2A	TTO8QRU	Strong	Biomarker	[113]
PPIA	TTL2ADK	Strong	Biomarker	[66]
PRDX5	TTLPJWH	Strong	Biomarker	[66]
PREP	TTNGKET	Strong	Biomarker	[44]
PRNP	TTY5F9C	Strong	Altered Expression	[114]
PTP4A3	TT7YM8D	Strong	Altered Expression	[115]
RARB	TTISP28	Strong	Biomarker	[116]
RNF43	TTD91BL	Strong	Biomarker	[117]
RXRB	TTKLV96	Strong	Biomarker	[44]
SERPINA1	TTA7UJC	Strong	Biomarker	[72]
SLC1A2	TT2F078	Strong	Biomarker	[73]
SP1	TTZEP6S	Strong	Altered Expression	[118]
SREBF2	TTRQ4AP	Strong	Biomarker	[44]
SSTR3	TTJX3UE	Strong	Altered Expression	[119]
TERT	TTQY2EJ	Strong	Altered Expression	[120]
TGFA	TTTLQFR	Strong	Therapeutic	[9]
TKTL1	TTNQ1J3	Strong	Altered Expression	[121]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[90]
TWIST1	TTX1MY7	Strong	Biomarker	[122]
TXNIP	TTTLDZK	Strong	Biomarker	[123]
TYMS	TTP1UKZ	Strong	Genetic Variation	[124]
VEGFC	TT0QUFV	Strong	Altered Expression	[125]
ADH7	TT3LE7P	Definitive	Altered Expression	[126]
ALOX5	TTSJ6Q4	Definitive	Biomarker	[127]
ASPH	TT2KHP7	Definitive	Altered Expression	[128]
CCNA2	TTAMQ62	Definitive	Altered Expression	[129]
CCND1	TTFCJ7S	Definitive	Biomarker	[37]
CEACAM6	TTIGH2W	Definitive	Biomarker	[130]
CFI	TT6ATLX	Definitive	Biomarker	[131]
CLDN18	TT6PKBX	Definitive	Altered Expression	[132]
CSNK1D	TTH30UI	Definitive	Posttranslational Modification	[35]
CSNK1E	TTA8PLI	Definitive	Posttranslational Modification	[35]
ELAVL1	TTPC9D0	Definitive	Altered Expression	[133]
EREG	TTYSB89	Definitive	Altered Expression	[134]
FHL1	TTI7ENL	Definitive	Altered Expression	[135]
HTATIP2	TTC6IX5	Definitive	Biomarker	[136]
MAGEA3	TTWSKHD	Definitive	Altered Expression	[137]
MCM7	TT1RM3F	Definitive	Altered Expression	[138]
NEDD4	TT1QU6G	Definitive	Altered Expression	[139]
NNT	TTKIH76	Definitive	Altered Expression	[140]
PDX1	TT8SGZK	Definitive	Altered Expression	[141]
PTPRZ1	TT4SEA8	Definitive	Biomarker	[142]
SOD2	TT9O4C5	Definitive	Biomarker	[90]
SRC	TT6PKBN	Definitive	Altered Expression	[143]
TDGF1	TTN7HMG	Definitive	Biomarker	[144]
TNK2	TTIET93	Definitive	Altered Expression	[145]
TNS4	TT1K65C	Definitive	Altered Expression	[146]
TP53	TT12KOD	Definitive	Genetic Variation	[147]
TRIM59	TT613U4	Definitive	Altered Expression	[148]
YES1	TT0SQ8J	Definitive	Altered Expression	[145]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC4A2	DTF7GAL	Definitive	Biomarker	[149]

This Disease Is Related to 9 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
FADS1	DE05S8C	Limited	Biomarker	[2]
GSTM1	DEYZEJA	Strong	Biomarker	[150]
GSTT1	DE3PKUG	Strong	Genetic Variation	[151]
MT2A	DEFKGT7	Strong	Biomarker	[152]
PLPP1	DE6WXTH	Strong	Biomarker	[44]
UPP1	DEFZWAX	Strong	Altered Expression	[153]
PGPEP1	DEVDR46	Definitive	Biomarker	[53]
UGT1A10	DEL5N6Y	Definitive	Altered Expression	[154]
UGT1A9	DE85D2P	Definitive	Altered Expression	[154]

This Disease Is Related to 269 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACE	OTDF1964	Limited	Genetic Variation	[155]
ALDH1A3	OT1C9NKQ	Limited	Biomarker	[2]
BNIP3	OT4SO7J4	Limited	Biomarker	[2]
CCNG2	OTII38K2	Limited	Biomarker	[156]
CDKN2D	OT2TTZPZ	Limited	Biomarker	[2]
CHFR	OTRAD2TT	Limited	Posttranslational Modification	[157]
CKB	OTUCKOTT	Limited	Altered Expression	[143]
CST7	OTQWZUVQ	Limited	Biomarker	[2]
DCBLD2	OTB71I02	Limited	Posttranslational Modification	[158]
DCC	OT2C1SHW	Limited	Genetic Variation	[159]
E2F4	OTB3JFH4	Limited	Genetic Variation	[160]
EEF1A2	OT9Z23K5	Limited	Biomarker	[2]
EPHX3	OTU7LW2F	Limited	Biomarker	[2]
FCGBP	OT63T6XQ	Limited	Biomarker	[2]
FILIP1	OTMZD6D4	Limited	Biomarker	[2]
FLCN	OTVM78XM	Limited	Genetic Variation	[161]
FSD1	OT8P6PT3	Limited	Biomarker	[2]
HLTF	OTRX2OSF	Limited	Posttranslational Modification	[162]
HRK	OTR4GWJ0	Limited	Posttranslational Modification	[163]
ICAM2	OT3E070F	Limited	Biomarker	[2]
ID4	OTPMJ39I	Limited	Biomarker	[2]
IL6R	OTCQL07Z	Limited	Biomarker	[2]
MAL	OTBM30SW	Limited	Posttranslational Modification	[164]
MARK1	OTP7KL47	Limited	Biomarker	[2]
MBD3L2	OTTG4S9O	Limited	Biomarker	[2]
MLF1	OTC5BKHU	Limited	Biomarker	[2]
MSX1	OT5U41ZP	Limited	Biomarker	[2]
MTSS1	OT5DTDO2	Limited	Biomarker	[2]
MX1	OT6X8G5T	Limited	Biomarker	[2]
PAX6	OTOC9876	Limited	Biomarker	[2]
PLAGL1	OTZAO900	Limited	Biomarker	[2]
PLIN2	OTRXJ9UN	Limited	Biomarker	[2]
PPIC	OTY5Q42N	Limited	Biomarker	[2]
RBP1	OTRP1MFC	Limited	Biomarker	[2]
SCRN1	OTELM5C2	Limited	Biomarker	[2]
SERPINB2	OT72QLZB	Limited	Biomarker	[2]
SNAI1	OTDPYAMC	Limited	Biomarker	[2]
SPRR2A	OT62ZU6B	Limited	Biomarker	[2]
SPZ1	OTQH8HJ5	Limited	Biomarker	[2]
TBX3	OTM64N7K	Limited	Biomarker	[2]
TFAP2C	OTUDIW05	Limited	Biomarker	[2]
TIA1	OTGPN3P8	Limited	Biomarker	[165]
TNFSF9	OTV9L89D	Limited	Biomarker	[2]
CD247	OT45FGUX	Disputed	Altered Expression	[166]
CLDN23	OTN5RV40	Disputed	Biomarker	[167]
EFNA1	OTU2NUA2	Disputed	Altered Expression	[168]
FXYD5	OT81DIOD	Disputed	Biomarker	[169]
GATA5	OTO81B63	Disputed	Posttranslational Modification	[170]
GSPT1	OT18H1B0	Disputed	Biomarker	[171]
HSPA13	OTYXMC4G	Disputed	Biomarker	[172]
ID3	OTUULW5Z	Disputed	Biomarker	[173]
IFITM1	OTECO1G8	Disputed	Altered Expression	[174]
KCMF1	OTVTKFAU	Disputed	Altered Expression	[175]
MIEN1	OTCQ8DAD	Disputed	Genetic Variation	[176]
MZB1	OT071TET	Disputed	Altered Expression	[177]
PAGE4	OT2VLWT0	Disputed	Altered Expression	[178]
PGA3	OT8EHCKQ	Disputed	Altered Expression	[179]
PGAP3	OTH9A75E	Disputed	Biomarker	[176]
PLCG2	OTGVC9MY	Disputed	Genetic Variation	[180]
RPL23	OTXI1YLM	Disputed	Biomarker	[181]
RPL6	OTRU71O4	Disputed	Altered Expression	[182]
RPS13	OTOMDIJ2	Disputed	Biomarker	[181]
SIAH1	OT29A838	Disputed	Genetic Variation	[183]
TP53BP2	OTOWJ2Y4	Disputed	Genetic Variation	[184]
TP53I11	OTFPDYZU	Disputed	Biomarker	[185]
ALDH3A1	OTAYZZE6	moderate	Altered Expression	[186]
ARL6IP5	OTYZ6BEQ	moderate	Biomarker	[187]
ASCL2	OT3D62WB	moderate	Altered Expression	[188]
CLDN3	OT71MN9S	moderate	Altered Expression	[132]
CST1	OTE4I83Q	moderate	Biomarker	[189]
ECM1	OT1K65VW	moderate	Biomarker	[190]
ERCC2	OT1C8HQ4	moderate	Genetic Variation	[191]
KLK10	OTD573EL	moderate	Altered Expression	[192]
KRT20	OT4RB40L	moderate	Biomarker	[96]
LRRC3B	OT9VDGPR	moderate	Biomarker	[193]
MAD2L1	OTXNGZCG	moderate	Biomarker	[194]
MAGED2	OTMEWNSE	moderate	Altered Expression	[47]
MUC2	OT3X4QVX	moderate	Altered Expression	[195]
MUC4	OTLT11V1	moderate	Biomarker	[196]
NELFB	OTCFH88S	moderate	Altered Expression	[197]
PPP1R1B	OTSIJMQ9	moderate	Altered Expression	[198]
SEM1	OTASLBM1	moderate	Altered Expression	[199]
SMAD4	OTWQWCKG	moderate	Biomarker	[200]
SOX17	OT9H4WWE	moderate	Biomarker	[201]
TFF2	OTRXB19X	moderate	Posttranslational Modification	[202]
TIMP3	OTDGQAD1	moderate	Biomarker	[203]
ABT1	OT9YGIDB	Strong	Biomarker	[44]
ACAD8	OT3JI5GB	Strong	Biomarker	[44]
ACTC1	OTJU04B1	Strong	Biomarker	[66]
ADAM23	OTVWT6JZ	Strong	Posttranslational Modification	[204]
ADAMTS9	OTV3Q0DS	Strong	Posttranslational Modification	[205]
AKAP12	OTCVRDDX	Strong	Biomarker	[206]
ALDH7A1	OTV57BZD	Strong	Biomarker	[44]
ALDOB	OT7FR69A	Strong	Biomarker	[66]
ANKRD33	OTPY8R95	Strong	Biomarker	[207]
APC	OTKV0TIK	Strong	Genetic Variation	[208]
ARFGAP2	OTIP5ZJ7	Strong	Biomarker	[44]
ARID1A	OTRWDV3P	Strong	Biomarker	[117]
ARID3B	OTUP9MS4	Strong	Altered Expression	[209]
ARPC1B	OTYE3DN2	Strong	Altered Expression	[210]
ATOH1	OTBZYG2R	Strong	Altered Expression	[211]
ATP6V0D2	OTMOZJO0	Strong	Biomarker	[90]
AXIN2	OTRMGQNU	Strong	Genetic Variation	[76]
B4GALNT2	OT85V4QV	Strong	Posttranslational Modification	[212]
BID	OTOSHSHU	Strong	Biomarker	[213]
BLVRB	OTHCFN2C	Strong	Biomarker	[66]
BOP1	OTMZMQDO	Strong	Biomarker	[44]
BTRC	OT2EZDGR	Strong	Genetic Variation	[214]
CACYBP	OTJMZD2T	Strong	Altered Expression	[215]
CAVIN3	OTOLBK79	Strong	Posttranslational Modification	[216]
CBFB	OTIAC6W4	Strong	Altered Expression	[217]
CCT7	OTQNM3CY	Strong	Biomarker	[44]
CD81	OTQFXNAZ	Strong	Biomarker	[218]
CDX2	OTCG4TSY	Strong	Biomarker	[219]
CIAPIN1	OTWS90F9	Strong	Biomarker	[220]
CNDP2	OTJR9436	Strong	Altered Expression	[221]
CNPY2	OTGY8ESX	Strong	Biomarker	[44]
COMMD5	OT6R7DXN	Strong	Altered Expression	[222]
COPS7A	OTLHKO3M	Strong	Biomarker	[44]
CPSF1	OTAU1KOM	Strong	Biomarker	[44]
CTNNA2	OTJ8G92T	Strong	Biomarker	[117]
CTNNBIP1	OTX9SBJG	Strong	Altered Expression	[223]
DACH1	OTMKNAGG	Strong	Altered Expression	[224]
DACT1	OT19Z704	Strong	Posttranslational Modification	[225]
DDB1	OTTR2L3Z	Strong	Biomarker	[44]
DDX53	OTHK3EGZ	Strong	Posttranslational Modification	[226]
DES	OTI09KBW	Strong	Biomarker	[66]
DLC1	OTP8LMCR	Strong	Therapeutic	[31]
DPAGT1	OTYEJAGZ	Strong	Biomarker	[44]
ECHS1	OTS0593S	Strong	Biomarker	[66]
EEF1A1	OT00THXS	Strong	Biomarker	[66]
EFNB1	OT7JJW8P	Strong	Altered Expression	[227]
ENO1	OTB1KWJS	Strong	Biomarker	[72]
ERCC1	OTNPYQHI	Strong	Biomarker	[228]
EXOSC5	OTADUQ7H	Strong	Biomarker	[44]
FA2H	OT8HA13U	Strong	Altered Expression	[229]
FAM168A	OTDXQCS5	Strong	Biomarker	[44]
FAT4	OT7QONNV	Strong	Biomarker	[95]
FBP1	OTQBANEP	Strong	Biomarker	[230]
FKBP2	OTHBZHX0	Strong	Biomarker	[44]
FOXD3	OTXYV6GO	Strong	Posttranslational Modification	[231]
FOXN3	OTOJYJZP	Strong	Altered Expression	[232]
GADD45A	OTDRV63V	Strong	Biomarker	[233]
GLI3	OTKDOE94	Strong	Biomarker	[117]
GMPR2	OTKZSZPE	Strong	Biomarker	[72]
GNL3	OTILGYO4	Strong	Biomarker	[234]
HIKESHI	OTPKV3UZ	Strong	Biomarker	[44]
HNRNPL	OT0DJX74	Strong	Biomarker	[44]
HOXA2	OT6G6ZIK	Strong	Biomarker	[92]
IDH3B	OTR89YF5	Strong	Biomarker	[44]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[91]
IGSF11	OTQEG2X1	Strong	Altered Expression	[235]
IL6ST	OT1N9C70	Strong	Biomarker	[236]
ING1	OTEZBRKW	Strong	Biomarker	[44]
INSIG1	OTZF5X1D	Strong	Altered Expression	[210]
KIF2C	OTJ8G3NP	Strong	Altered Expression	[237]
KLF6	OTQY9S7F	Strong	Genetic Variation	[238]
KLK12	OTNYK59J	Strong	Genetic Variation	[239]
KLK13	OT8LOD2U	Strong	Altered Expression	[240]
KMT2C	OTC59BCO	Strong	Biomarker	[95]
KRT8	OTTM4X11	Strong	Biomarker	[72]
LGALS7	OTMSVI7R	Strong	Altered Expression	[241]
LIMS2	OTZ7IIPM	Strong	Posttranslational Modification	[242]
MPHOSPH8	OTYI2WNS	Strong	Biomarker	[243]
MRPL13	OT6D8Y9G	Strong	Biomarker	[44]
MRPS11	OTEERNWQ	Strong	Biomarker	[44]
MRPS18B	OT1K9PFX	Strong	Biomarker	[44]
MUC6	OTPVL723	Strong	Biomarker	[117]
MYCT1	OTZ8A9L3	Strong	Altered Expression	[244]
NAXD	OTPO2GM2	Strong	Biomarker	[44]
NBAS	OTW9IBRI	Strong	Biomarker	[44]
NCR3LG1	OT15YWU7	Strong	Altered Expression	[245]
NDUFA2	OTNSTATK	Strong	Biomarker	[44]
NDUFS1	OTTIZDFR	Strong	Biomarker	[44]
NDUFV1	OTEVK4WW	Strong	Biomarker	[44]
NEIL1	OTHBU5DJ	Strong	Altered Expression	[246]
NOP56	OTT67SRZ	Strong	Biomarker	[44]
PA2G4	OT7IG7HT	Strong	Biomarker	[44]
PDCD6	OT2YA5M8	Strong	Altered Expression	[224]
PDHA1	OTGEU8IK	Strong	Biomarker	[44]
PDIA3	OTHPQ0Q3	Strong	Altered Expression	[247]
PFKFB1	OTTHX4NB	Strong	Altered Expression	[110]
PFKFB4	OTQYEXL2	Strong	Altered Expression	[110]
PGAM1	OTZ5DB06	Strong	Biomarker	[72]
PLCE1	OTJISZOX	Strong	Biomarker	[248]
POLR3K	OTZCSF6A	Strong	Biomarker	[44]
PPP2R1A	OTYA3GB4	Strong	Biomarker	[44]
PRDM2	OT8L7CGX	Strong	Genetic Variation	[249]
PRKAA1	OT7TNF0L	Strong	Biomarker	[16]
PRKAB1	OT1OG4QZ	Strong	Biomarker	[44]
PRPF19	OTQ1STV3	Strong	Biomarker	[44]
PTOV1	OT94WT5X	Strong	Biomarker	[44]
PTPA	OTRGFOI7	Strong	Biomarker	[44]
PTPRF	OTH5KF2D	Strong	Biomarker	[44]
PTPRG	OT9N2WOF	Strong	Posttranslational Modification	[250]
PUS1	OTS2DQ0N	Strong	Biomarker	[44]
PYCARD	OT67RON3	Strong	Biomarker	[2]
RAD23A	OTBPAWHX	Strong	Biomarker	[44]
RANBP10	OT0ZNZ0B	Strong	Biomarker	[44]
RARRES1	OTETUPP5	Strong	Biomarker	[116]
RASSF2	OT2JHDO4	Strong	Posttranslational Modification	[251]
RBX1	OTYA1UIO	Strong	Altered Expression	[252]
REC8	OT6JAVXE	Strong	Altered Expression	[253]
REG1A	OTMHUH1D	Strong	Posttranslational Modification	[254]
RHOBTB2	OT2DATFX	Strong	Genetic Variation	[255]
RPL13	OTFKNTD6	Strong	Biomarker	[44]
RPL18	OTJCH62J	Strong	Biomarker	[44]
RPS15	OT0WYZYG	Strong	Biomarker	[44]
RPS19	OTBKGP48	Strong	Biomarker	[44]
RPS21	OT6P58W6	Strong	Biomarker	[44]
RPS26	OTBYTA6A	Strong	Biomarker	[44]
RPS6	OTT4D1LN	Strong	Biomarker	[44]
RRP9	OT97EAV4	Strong	Biomarker	[44]
SELENBP1	OT3NZNTR	Strong	Biomarker	[66]
SERBP1	OTZVSU0X	Strong	Biomarker	[44]
SETBP1	OTKGCOSR	Strong	Biomarker	[256]
SNRPB	OT3UJ4ZU	Strong	Biomarker	[44]
SNX5	OT6ZOWMU	Strong	Biomarker	[44]
SOSTDC1	OTAKDNSM	Strong	Biomarker	[257]
SPPL2A	OTCVF6MM	Strong	Altered Expression	[91]
ST3GAL6	OTB17Q43	Strong	Posttranslational Modification	[212]
SUCLG1	OTDCSPXH	Strong	Biomarker	[44]
SYMPK	OTYAUDXV	Strong	Biomarker	[44]
TACC1	OTGX20TE	Strong	Altered Expression	[258]
TAF15	OTNE038N	Strong	Biomarker	[44]
TINF2	OT861N2N	Strong	Altered Expression	[259]
TMEFF2	OT1WZ2QO	Strong	Posttranslational Modification	[260]
TMEM63A	OTIUZ0C7	Strong	Biomarker	[44]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[261]
TP53INP1	OT2363Z9	Strong	Altered Expression	[262]
TPM3	OT5RU5G6	Strong	Biomarker	[72]
TRAK1	OTMQVYNP	Strong	Biomarker	[263]
TRAP1	OTNG0L8J	Strong	Biomarker	[44]
ABHD11	OTJE9UZY	Definitive	Altered Expression	[264]
ADIPOR2	OT2HDTL8	Definitive	Biomarker	[265]
ANXA4	OTUCRYXL	Definitive	Biomarker	[266]
ANXA7	OTLMD0TK	Definitive	Altered Expression	[267]
AP2A1	OTEFZB21	Definitive	Biomarker	[268]
ARHGDIB	OT9PD6CS	Definitive	Biomarker	[269]
DHDH	OTKA2AL6	Definitive	Altered Expression	[270]
DYNLRB1	OTWVKOFB	Definitive	Genetic Variation	[271]
EIF4A3	OTYYFE7K	Definitive	Altered Expression	[272]
ENDOG	OT5IM7B3	Definitive	Altered Expression	[273]
FBLN1	OT5MHHOP	Definitive	Altered Expression	[274]
FRZB	OTTO3DPY	Definitive	Biomarker	[275]
FZD5	OTXFFY56	Definitive	Altered Expression	[276]
GKN1	OT7ZYFQ9	Definitive	Altered Expression	[277]
HIVEP3	OTM3QT3L	Definitive	Altered Expression	[278]
INPPL1	OTCDAVBQ	Definitive	Altered Expression	[279]
IQGAP2	OTX2UA7P	Definitive	Posttranslational Modification	[280]
KRT18	OTVLQFIP	Definitive	Biomarker	[96]
MGAT5	OTU4DD4G	Definitive	Altered Expression	[281]
MOS	OTNMQPFJ	Definitive	Altered Expression	[282]
OPCML	OT93PQ6Y	Definitive	Altered Expression	[145]
PCDH10	OT2GIT0E	Definitive	Biomarker	[283]
PDCD5	OT6T2DDL	Definitive	Biomarker	[284]
PITX1	OTA0UN4C	Definitive	Altered Expression	[285]
PIWIL1	OT7CRGZ3	Definitive	Biomarker	[286]
POU2F1	OTK7ELJ0	Definitive	Altered Expression	[276]
PRKD2	OTIFSVI8	Definitive	Posttranslational Modification	[35]
PTPRA	OTZA82J1	Definitive	Biomarker	[142]
RAB23	OTBAKFBR	Definitive	Biomarker	[287]
RHOC	OTOLE1FT	Definitive	Biomarker	[288]
RNASE1	OTKZ7CO9	Definitive	Altered Expression	[145]
RND3	OTXMXPIH	Definitive	Altered Expression	[289]
RPRM	OTNNBAS1	Definitive	Posttranslational Modification	[290]
RPS27	OTFXKY7P	Definitive	Altered Expression	[291]
SULF1	OTJCNCO0	Definitive	Posttranslational Modification	[292]
TSPYL5	OT7QEI2X	Definitive	Posttranslational Modification	[293]

References

• [1] Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci. 2007 Mar;96(1):21-9.
• [2] Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
• [3] [Effect of B-RAF-specific RNA interference on gastric cancer BGC823 cell line].Yi Chuan. 2007 May;29(5):537-40. doi: 10.1360/yc-007-0537.
• [4] A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.Nat Genet. 2007 May;39(5):605-13. doi: 10.1038/ng2030. Epub 2007 Apr 22.
• [5] Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.Cancer Res. 2001 Nov 1;61(21):7727-30.
• [6] Methylation pattern analysis using high-throughput microarray of solid-phase hyperbranched rolling circle amplification products.Electrophoresis. 2008 Feb;29(3):626-33. doi: 10.1002/elps.200700375.
• [7] DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.Eur J Cancer. 2011 Aug;47(12):1817-25. doi: 10.1016/j.ejca.2011.02.024. Epub 2011 Mar 31.
• [8] Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.BMC Cancer. 2015 Oct 16;15:718. doi: 10.1186/s12885-015-1721-z.
• [9] Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol. 2005 Apr;55(4):393-403. doi: 10.1007/s00280-004-0904-0. Epub 2004 Oct 5.
• [10] Expression and function of heme oxygenase-1 in human gastric cancer.Exp Biol Med (Maywood). 2012 Apr;237(4):362-71. doi: 10.1258/ebm.2011.011193. Epub 2012 Apr 4.
• [11] The role of IGFBP3 functional polymorphisms in the risk of gastric cancer in a high-risk Chinese population.Eur J Cancer Prev. 2008 Apr;17(2):82-7. doi: 10.1097/CEJ.0b013e32809b4cff.
• [12] EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.Oncol Rep. 2008 Dec;20(6):1569-75.
• [13] Epithelioid gastrointestinal stromal tumor of the stomach with liver metastases in a 12-year-old girl: aspiration cytology and molecular study.Pediatr Dev Pathol. 2002 Jul-Aug;5(4):386-94. doi: 10.1007/s10024-001-0250-8. Epub 2002 Jun 17.
• [14] Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing.Genes Chromosomes Cancer. 2015 Mar;54(3):177-84. doi: 10.1002/gcc.22230. Epub 2014 Nov 27.
• [15] YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.Cancer Res. 2018 Jun 15;78(12):3306-3320. doi: 10.1158/0008-5472.CAN-17-3487. Epub 2018 Apr 18.
• [16] Loss-of-function variants in ATM confer risk of gastric cancer.Nat Genet. 2015 Aug;47(8):906-10. doi: 10.1038/ng.3342. Epub 2015 Jun 22.
• [17] Reg IV enhances peritoneal metastasis in gastric carcinomas.Cell Prolif. 2009 Feb;42(1):110-21. doi: 10.1111/j.1365-2184.2008.00577.x.
• [18] Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.Nat Genet. 2014 Jun;46(6):583-7. doi: 10.1038/ng.2984. Epub 2014 May 11.
• [19] Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer.Oncol Rep. 2003 Sep-Oct;10(5):1375-80.
• [20] PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues.Hepatogastroenterology. 2008 Jul-Aug;55(85):1480-3.
• [21] Integrated Analysis of Mouse and Human Gastric Neoplasms Identifies Conserved microRNA Networks in Gastric Carcinogenesis.Gastroenterology. 2019 Mar;156(4):1127-1139.e8. doi: 10.1053/j.gastro.2018.11.052. Epub 2018 Nov 28.
• [22] Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line.Oncol Rep. 2008 Dec;20(6):1545-51.
• [23] Loss of caspase-2, -6 and -7 expression in gastric cancers.APMIS. 2004 Jun;112(6):330-5. doi: 10.1111/j.1600-0463.2004.apm1120602.x.
• [24] Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):473-82.
• [25] Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer.Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6800-6. doi: 10.1158/1078-0432.CCR-05-0943.
• [26] The Ku antigen-recombination signal-binding protein Jkappa complex binds to the nuclear factor-kappaB p50 promoter and acts as a positive regulator of p50 expression in human gastric cancer cells.J Biol Chem. 2004 Jan 2;279(1):231-7. doi: 10.1074/jbc.M308609200. Epub 2003 Oct 21.
• [27] Absence of beta-tubulin gene mutation in gastric carcinoma.Gastric Cancer. 2003;6(2):108-12. doi: 10.1007/s10120-003-0235-6.
• [28] Concurrent expression of aryl hydrocarbon receptor and CYP1A1 but not CYP1A1 MspI polymorphism is correlated with gastric cancers raised in Dalian, China.Cancer Lett. 2006 Aug 28;240(2):253-60. doi: 10.1016/j.canlet.2005.09.020. Epub 2005 Dec 6.
• [29] Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.Gastroenterology. 2013 Dec;145(6):1312-22.e1-8. doi: 10.1053/j.gastro.2013.08.050. Epub 2013 Aug 29.
• [30] Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.Cancer Res. 2016 Jan 15;76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. Epub 2015 Dec 30.
• [31] Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12492-7. doi: 10.1073/pnas.1507491112. Epub 2015 Sep 23.
• [32] Modulation of anti-apoptosis by endogenous IAP expression in MKN45 human gastric cancer cells.Anticancer Res. 2005 Jul-Aug;25(4):2713-7.
• [33] Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas.APMIS. 2006 Sep;114(9):646-50. doi: 10.1111/j.1600-0463.2006.apm_417.x.
• [34] Bidirectional alteration of Cav-1 expression is associated with mitogenic conversion of its function in gastric tumor progression.BMC Cancer. 2017 Nov 15;17(1):766. doi: 10.1186/s12885-017-3770-y.
• [35] Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2.EMBO J. 2007 Nov 14;26(22):4619-33. doi: 10.1038/sj.emboj.7601891. Epub 2007 Oct 25.
• [36] Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression.Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30. doi: 10.1016/j.bbrc.2007.05.023. Epub 2007 May 15.
• [37] Cyclin D1/cdk4, estrogen receptors and , in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric carcinogenesis: immunohistochemical study.J Toxicol Sci. 2011 Jun;36(3):373-8. doi: 10.2131/jts.36.373.
• [38] P27kip1 regulates the apoptotic response of gastric epithelial cells to Helicobacter pylori.Gut. 2004 Jun;53(6):797-804. doi: 10.1136/gut.2003.032144.
• [39] Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor.Cancer Biomark. 2017 Jul 4;19(3):241-248. doi: 10.3233/CBM-160256.
• [40] Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
• [41] Oncogenic ERBB3 mutations in human cancers.Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012.
• [42] Helicobacter pylori infection and family history of gastric cancer decrease expression of FHIT tumor suppressor gene in gastric mucosa of dyspeptic patients.Helicobacter. 2009 Oct;14(5):126-34. doi: 10.1111/j.1523-5378.2009.00715.x.
• [43] Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.Oncotarget. 2016 Jul 19;7(29):45462-45478. doi: 10.18632/oncotarget.9990.
• [44] A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.PLoS One. 2011 Feb 18;6(2):e16694. doi: 10.1371/journal.pone.0016694.
• [45] Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients.Clin Exp Med. 2015 Aug;15(3):415-20. doi: 10.1007/s10238-014-0299-0. Epub 2014 Jul 18.
• [46] Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae.Oncol Rep. 2008 Feb;19(2):401-6.
• [47] Utility of molecular genetic signatures in the delineation of gastric neoplasia.Cancer. 2006 Apr 1;106(7):1480-8. doi: 10.1002/cncr.21758.
• [48] Thymidylate synthase and methylenetetrahy-drofolate reductase gene polymorphisms and gastric cancer susceptibility in a population of Northern Brazil.Genet Mol Res. 2015 Aug 21;14(3):10001-6. doi: 10.4238/2015.August.21.6.
• [49] Multicellular Human Gastric-Cancer Spheroids Mimic the Glycosylation Phenotype of Gastric Carcinomas.Molecules. 2018 Oct 30;23(11):2815. doi: 10.3390/molecules23112815.
• [50] Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis.Biologicals. 2009 Jan;37(1):18-25. doi: 10.1016/j.biologicals.2008.08.002. Epub 2008 Oct 10.
• [51] Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications.BMC Gastroenterol. 2014 Jan 10;14:9. doi: 10.1186/1471-230X-14-9.
• [52] Orphan nuclear receptor Nur77 translocates to mitochondria in the early phase of apoptosis induced by synthetic chenodeoxycholic acid derivatives in human stomach cancer cell line SNU-1.Ann N Y Acad Sci. 2003 Dec;1010:171-7. doi: 10.1196/annals.1299.029.
• [53] Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection.Aliment Pharmacol Ther. 2017 Oct;46(8):758-767. doi: 10.1111/apt.14263. Epub 2017 Aug 11.
• [54] The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.Helicobacter. 2008 Jun;13(3):174-82. doi: 10.1111/j.1523-5378.2008.00597.x.
• [55] Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases.Br J Cancer. 2009 Jan 13;100(1):153-9. doi: 10.1038/sj.bjc.6604806. Epub 2008 Dec 2.
• [56] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [57] A genetic variant in 3'-untranslated region of cyclooxygenases-2 gene is associated with risk of gastric cancer in a Chinese population.DNA Cell Biol. 2012 Jul;31(7):1252-7. doi: 10.1089/dna.2012.1615. Epub 2012 Mar 2.
• [58] Phosphorylation of the gastric tumor suppressor RUNX3 following H. pylori infection results in its localization to the cytoplasm.J Cell Physiol. 2012 Mar;227(3):1071-80. doi: 10.1002/jcp.22820.
• [59] Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications.Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8. doi: 10.1097/PAI.0b013e31802c4f21.
• [60] Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.Carcinogenesis. 2008 Mar;29(3):480-90. doi: 10.1093/carcin/bgm281. Epub 2008 Jan 3.
• [61] MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523.
• [62] Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance.Oncotarget. 2017 Jul 11;8(28):45848-45861. doi: 10.18632/oncotarget.17435.
• [63] Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.Mol Cancer Res. 2008 Oct;6(10):1554-66. doi: 10.1158/1541-7786.MCR-08-0166.
• [64] Expression of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells. PLoS One. 2013;8(1):e54774. doi: 10.1371/journal.pone.0054774. Epub 2013 Jan 30.
• [65] Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread.Cancer Biol Ther. 2007 Aug;6(8):1218-26. doi: 10.4161/cbt.6.8.4412. Epub 2007 Aug 10.
• [66] Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers.Oncol Rep. 2009 Jun;21(6):1429-37. doi: 10.3892/or_00000371.
• [67] Myenteric denervation in gastric carcinogenesis: differential modulation of nitric oxide and annexin-A1.Int J Clin Exp Pathol. 2013;6(1):13-23. Epub 2012 Nov 20.
• [68] Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun. 2005 Aug 19;334(1):207-12. doi: 10.1016/j.bbrc.2005.05.204.
• [69] Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.Int Immunopharmacol. 2001 Nov;1(12):2063-80. doi: 10.1016/s1567-5769(01)00118-7.
• [70] Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer.Hepatogastroenterology. 2007 Oct-Nov;54(79):1934-40.
• [71] Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas.Oncogene. 2006 Apr 27;25(18):2666-73. doi: 10.1038/sj.onc.1209297.
• [72] Diverse proteomic alterations in gastric adenocarcinoma.Proteomics. 2004 Oct;4(10):3276-87. doi: 10.1002/pmic.200300916.
• [73] CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 2011 Apr 6;3(77):77ra30. doi: 10.1126/scitranslmed.3001423.
• [74] CD9 expression in gastric cancer and its significance.J Surg Res. 2004 Apr;117(2):208-15. doi: 10.1016/j.jss.2004.01.014.
• [75] Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein and its nuclear accumulation is linked to poor prognosis for human gastric cancer.Exp Cell Res. 2006 Apr 15;312(7):962-73. doi: 10.1016/j.yexcr.2005.12.015. Epub 2006 Jan 19.
• [76] Clinical relevance of breast and gastric cancer-associated polymorphisms as potential susceptibility markers for oral clefts in the Brazilian population.BMC Med Genet. 2017 Apr 4;18(1):39. doi: 10.1186/s12881-017-0390-y.
• [77] CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas.Clin Exp Med. 2017 Feb;17(1):121-129. doi: 10.1007/s10238-015-0400-3. Epub 2015 Nov 14.
• [78] Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression.Histol Histopathol. 2008 May;23(5):515-21. doi: 10.14670/HH-23.515.
• [79] CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.Br J Cancer. 2011 Mar 29;104(7):1126-34. doi: 10.1038/bjc.2011.24. Epub 2011 Mar 1.
• [80] Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Pharmacogenomics J. 2012 Apr;12(2):119-27. doi: 10.1038/tpj.2010.87. Epub 2010 Dec 21.
• [81] Polymorphisms and mutations of the folate receptor-alpha gene and risk of gastric cancer in a Chinese population.Int J Mol Med. 2005 Apr;15(4):627-32.
• [82] Adipokines and ghrelin in gastric cancer cachexia.World J Gastroenterol. 2008 Jun 21;14(23):3633-41. doi: 10.3748/wjg.14.3633.
• [83] Association of heparanase gene (HPSE-1) single nucleotide polymorphisms with gastric cancer.J Surg Oncol. 2010 Jul 1;102(1):68-72. doi: 10.1002/jso.21584.
• [84] Gene expression analysis in the lung of the rasH2 transgenic mouse at week 4 prior to induction of malignant tumor formation by urethane and N-methylolacrylamide.J Toxicol Sci. 2015 Dec;40(6):685-700. doi: 10.2131/jts.40.685.
• [85] Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression. PLoS One. 2012;7(2):e31207. doi: 10.1371/journal.pone.0031207. Epub 2012 Feb 20.
• [86] Sex steroid metabolism in human gastric mucosa: 17 beta-hydroxysteroid dehydrogenase type 2 in normal, inflamed and neoplastic gastric tissues.Anticancer Res. 2003 Sep-Oct;23(5A):3889-97.
• [87] HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer.Histopathology. 2011 Apr;58(5):669-78. doi: 10.1111/j.1365-2559.2011.03818.x. Epub 2011 Mar 30.
• [88] Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer.Carcinogenesis. 2007 Jan;28(1):118-23. doi: 10.1093/carcin/bgl130. Epub 2006 Aug 2.
• [89] Inflammatory cytokine gene polymorphisms in gastric cancer cases' and controls' family members from Chinese areas at high cancer prevalence.Cancer Lett. 2008 Nov 8;270(2):250-9. doi: 10.1016/j.canlet.2008.05.013. Epub 2008 Jun 18.
• [90] Expression of acidosis-dependent genes in human cancer nests.Mol Clin Oncol. 2014 Nov;2(6):1160-1166. doi: 10.3892/mco.2014.344. Epub 2014 Jul 11.
• [91] Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma.J Surg Oncol. 2012 Jun 15;105(8):780-5. doi: 10.1002/jso.22108. Epub 2011 Oct 19.
• [92] Quantitative expression of the homeobox and integrin genes in human gastric carcinoma.Int J Mol Med. 2007 Oct;20(4):621-9.
• [93] Detection of potassium currents and regulation of multidrug resistance by potassium channels in human gastric cancer cells. Cell Biol Int. 2007 Jul;31(7):741-7. doi: 10.1016/j.cellbi.2007.01.008. Epub 2007 Jan 21.
• [94] Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines.Med Oncol. 2007;24(3):345-50. doi: 10.1007/s12032-007-0015-y.
• [95] Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.Nat Genet. 2012 May;44(5):570-4. doi: 10.1038/ng.2246.
• [96] Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.Hepatogastroenterology. 2008 May-Jun;55(84):1131-5.
• [97] Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer.Ann Oncol. 2007 Feb;18(2):311-6. doi: 10.1093/annonc/mdl394. Epub 2006 Oct 30.
• [98] Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer.Oncol Rep. 2007 Aug;18(2):329-36.
• [99] c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice.Cancer Res. 2008 Jul 1;68(13):5031-9. doi: 10.1158/0008-5472.CAN-07-6332.
• [100] Volumetric parameters on (18)F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET.BMC Cancer. 2019 Aug 8;19(1):790. doi: 10.1186/s12885-019-5935-3.
• [101] Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10. J Nutr Biochem. 2012 Nov;23(11):1434-9. doi: 10.1016/j.jnutbio.2011.09.004. Epub 2012 Jan 27.
• [102] Association of MMP7 -181AG Promoter Polymorphism with Gastric Cancer Risk: INFLUENCE OF NICOTINE IN DIFFERENTIAL ALLELE-SPECIFIC TRANSCRIPTION VIA INCREASED PHOSPHORYLATION OF cAMP-RESPONSE ELEMENT-BINDING PROTEIN (CREB).J Biol Chem. 2015 Jun 5;290(23):14391-406. doi: 10.1074/jbc.M114.630129. Epub 2015 Apr 6.
• [103] Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer.Br J Cancer. 2012 Jun 26;107(1):137-42. doi: 10.1038/bjc.2012.235. Epub 2012 May 29.
• [104] Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.PLoS One. 2014 Apr 11;9(4):e94554. doi: 10.1371/journal.pone.0094554. eCollection 2014.
• [105] p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer.Mol Cancer Res. 2007 May;5(5):423-33. doi: 10.1158/1541-7786.MCR-06-0407.
• [106] Long Noncoding RNA (lncRNA) MIR22HG Suppresses Gastric Cancer Progression through Attenuating NOTCH2 Signaling.Med Sci Monit. 2019 Jan 23;25:656-665. doi: 10.12659/MSM.912813.
• [107] Natriuretic peptide receptor A inhibition suppresses gastric cancer development through reactive oxygen species-mediated G2/M cell cycle arrest and cell death.Free Radic Biol Med. 2016 Oct;99:593-607. doi: 10.1016/j.freeradbiomed.2016.08.019. Epub 2016 Sep 12.
• [108] Prospective enterprise-level molecular genotyping of a cohort of cancer patients.J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23.
• [109] GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology.Lab Invest. 2006 Jan;86(1):94-100. doi: 10.1038/labinvest.3700360.
• [110] Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.Acta Biochim Pol. 2006;53(4):789-99. Epub 2006 Dec 4.
• [111] Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.Oncotarget. 2016 Feb 2;7(5):6201-20. doi: 10.18632/oncotarget.6641.
• [112] Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma.Oncogene. 2005 Jan 6;24(1):157-64. doi: 10.1038/sj.onc.1207832.
• [113] Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.Cancer Res. 2008 Jun 1;68(11):4277-86. doi: 10.1158/0008-5472.CAN-07-6517.
• [114] Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS.FASEB J. 2007 Jul;21(9):2247-56. doi: 10.1096/fj.06-7799com. Epub 2007 Apr 4.
• [115] High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.Ann Surg Oncol. 2009 Jan;16(1):208-19. doi: 10.1245/s10434-008-0214-6. Epub 2008 Nov 14.
• [116] DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation.Cancer. 2005 Oct 15;104(8):1609-19. doi: 10.1002/cncr.21392.
• [117] Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.Nat Genet. 2014 Jun;46(6):573-82. doi: 10.1038/ng.2983. Epub 2014 May 11.
• [118] Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer.Clin Exp Metastasis. 2005;22(3):205-13. doi: 10.1007/s10585-005-5684-3.
• [119] Expression of somatostatin receptor subtype 3 in the gastric mucosa of dyspeptic patients in relation to Helicobacter pylori infection and a family history of gastric cancer.J Gastroenterol Hepatol. 2008 Mar;23(3):424-9. doi: 10.1111/j.1440-1746.2007.05094.x. Epub 2007 Aug 7.
• [120] Abacavir induces the transcriptional activity of YY1 and other oncogenic transcription factors in gastric cancer cells.Antiviral Res. 2020 Feb;174:104695. doi: 10.1016/j.antiviral.2019.104695. Epub 2019 Dec 14.
• [121] Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer.Oncol Rep. 2006 Oct;16(4):657-61.
• [122] Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells. Clin Exp Metastasis. 2009;26(8):1013-23. doi: 10.1007/s10585-009-9291-6. Epub 2009 Oct 6.
• [123] Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease.Anticancer Res. 2002 Nov-Dec;22(6C):4045-8.
• [124] The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.Cancer Chemother Pharmacol. 2009 Apr;63(5):911-8. doi: 10.1007/s00280-008-0815-6. Epub 2008 Aug 15.
• [125] Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early gastric cancer.J Surg Oncol. 2009 Mar 1;99(3):148-53. doi: 10.1002/jso.21228.
• [126] Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with gastric cancer.Dig Dis Sci. 2008 Aug;53(8):2101-5. doi: 10.1007/s10620-007-0135-4. Epub 2008 Jan 30.
• [127] Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth. Cancer Lett. 2010 Jun 28;292(2):237-45.
• [128] Overexpression of humbug promotes malignant progression in human gastric cancer cells.Oncol Rep. 2008 Mar;19(3):795-800.
• [129] Prognostic significance of cyclin A in gastric cancer.Int J Cancer. 2006 Oct 15;119(8):1897-901. doi: 10.1002/ijc.21944.
• [130] Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma.Genet Mol Res. 2014 Sep 26;13(3):7686-97. doi: 10.4238/2014.September.26.6.
• [131] Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis.Clin Chim Acta. 2007 Feb;377(1-2):119-26. doi: 10.1016/j.cca.2006.09.005. Epub 2006 Sep 14.
• [132] Gastric and intestinal claudin expression at the invasive front of gastric carcinoma.Cancer Sci. 2007 Jul;98(7):1014-9. doi: 10.1111/j.1349-7006.2007.00490.x. Epub 2007 Apr 24.
• [133] NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis.Gastroenterology. 2008 Dec;135(6):2030-42, 2042.e1-3. doi: 10.1053/j.gastro.2008.08.009. Epub 2008 Aug 20.
• [134] Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts.Cancer Sci. 2017 Dec;108(12):2342-2351. doi: 10.1111/cas.13411. Epub 2017 Oct 21.
• [135] Clinical significance of loss of Fhl1 expression in human gastric cancer.Ann Surg Oncol. 2008 Aug;15(8):2293-300. doi: 10.1245/s10434-008-9904-3. Epub 2008 May 9.
• [136] Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis.Int J Cancer. 2009 Feb 1;124(3):713-21. doi: 10.1002/ijc.23967.
• [137] Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.World J Gastroenterol. 2006 Sep 21;12(35):5651-7. doi: 10.3748/wjg.v12.i35.5651.
• [138] Amplified 7q21-22 gene MCM7 and its intronic miR-25 suppress COL1A2 associated genes to sustain intestinal gastric cancer features.Mol Carcinog. 2017 Jun;56(6):1590-1602. doi: 10.1002/mc.22614. Epub 2017 Jan 25.
• [139] Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas.APMIS. 2008 Sep;116(9):779-84. doi: 10.1111/j.1600-0463.2008.00999.x.
• [140] Nicotinamide nucleotide transhydrogenase-mediated redox homeostasis promotes tumor growth and metastasis in gastric cancer.Redox Biol. 2018 Sep;18:246-255. doi: 10.1016/j.redox.2018.07.017. Epub 2018 Jul 21.
• [141] Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer.Carcinogenesis. 2008 Jul;29(7):1327-33. doi: 10.1093/carcin/bgn112. Epub 2008 May 13.
• [142] Protein tyrosine-phosphatase expression profiling in gastric cancer tissues.Cancer Lett. 2006 Oct 8;242(1):95-103. doi: 10.1016/j.canlet.2005.10.046. Epub 2005 Dec 7.
• [143] Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis.PLoS One. 2015 Oct 13;10(10):e0140492. doi: 10.1371/journal.pone.0140492. eCollection 2015.
• [144] Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.Histopathology. 2008 Apr;52(5):560-8. doi: 10.1111/j.1365-2559.2008.02971.x. Epub 2008 Feb 28.
• [145] Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray.World J Gastroenterol. 2006 Nov 21;12(43):6949-54. doi: 10.3748/wjg.v12.i43.6949.
• [146] Prognostic relevance of Tensin4 expression in human gastric cancer.Ann Surg Oncol. 2008 Sep;15(9):2606-13. doi: 10.1245/s10434-008-9989-8. Epub 2008 Jul 9.
• [147] Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.JCI Insight. 2018 Aug 9;3(15):e121364. doi: 10.1172/jci.insight.121364. eCollection 2018 Aug 9.
• [148] TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53.Gastroenterology. 2014 Nov;147(5):1043-54. doi: 10.1053/j.gastro.2014.07.021. Epub 2014 Jul 18.
• [149] Expression of anion exchanger 2 in human gastric cancer.Exp Oncol. 2008 Mar;30(1):81-7.
• [150] Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility.Tumour Biol. 2011 Feb;32(1):215-22. doi: 10.1007/s13277-010-0115-8. Epub 2010 Sep 29.
• [151] Gastric carcinogenesis: Possible role of polymorphisms of GSTM1, GSTT1, and GSTP1 genes.Scand J Gastroenterol. 2008;43(4):431-9. doi: 10.1080/00365520701742930.
• [152] Differential induction of Mn-containing superoxide dismutase by paraquat in peripheral lymphocytes of normal subjects and gastric cancer patients. Mol Cells. 2003 Aug 31;16(1):13-8.
• [153] Up-regulated expression of the uridine phosphorylase gene in human gastric tumors is correlated with a favorable prognosis.Anticancer Res. 2006 Nov-Dec;26(6C):4647-51.
• [154] Differential expression of the UGT1A family of genes in stomach cancer tissues.Tumour Biol. 2015 Aug;36(8):5831-7. doi: 10.1007/s13277-015-3253-1. Epub 2015 Feb 25.
• [155] The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1206-12. doi: 10.1158/1055-9965.EPI-05-0934.
• [156] Cyclin G2 suppresses Wnt/-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1.J Exp Clin Cancer Res. 2018 Dec 14;37(1):317. doi: 10.1186/s13046-018-0973-2.
• [157] Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.World J Gastroenterol. 2008 Aug 28;14(32):5000-7. doi: 10.3748/wjg.14.5000.
• [158] Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion.Mol Cancer Res. 2008 Feb;6(2):222-30. doi: 10.1158/1541-7786.MCR-07-0142.
• [159] The role of the Deleted Colon Cancer (DCC) gene in colorectal and gastric cancer.Cancer Invest. 2003 Jun;21(3):484-5. doi: 10.1081/cnv-120018241.
• [160] Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors.Cancer Res. 1997 Jun 15;57(12):2350-3.
• [161] Birt-Hogg-Dub (BHD) gene mutations in human gastric cancer with high frequency microsatellite instability.Cancer Lett. 2007 Apr 8;248(1):103-11. doi: 10.1016/j.canlet.2006.06.005. Epub 2006 Jul 25.
• [162] Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis.Mol Cancer. 2006 Jun 8;5:23. doi: 10.1186/1476-4598-5-23.
• [163] Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.Clin Cancer Res. 2003 Dec 15;9(17):6410-8.
• [164] MAL promoter hypermethylation as a novel prognostic marker in gastric cancer.Br J Cancer. 2008 Dec 2;99(11):1802-7. doi: 10.1038/sj.bjc.6604777. Epub 2008 Nov 11.
• [165] miR-487a promotes progression of gastric cancer by targeting TIA1.Biochimie. 2018 Nov;154:119-126. doi: 10.1016/j.biochi.2018.08.006. Epub 2018 Aug 23.
• [166] CD3 zeta expression of regional lymph node and peripheral blood lymphocytes in gastric cancer.Anticancer Res. 2004 May-Jun;24(3b):2123-6.
• [167] CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family.Int J Mol Med. 2003 Jun;11(6):683-9.
• [168] EPHA2/EFNA1 expression in human gastric cancer.Cancer Sci. 2005 Jan;96(1):42-7. doi: 10.1111/j.1349-7006.2005.00007.x.
• [169] Clinical significance of dysadherin expression in gastric cancer patients.Clin Cancer Res. 2004 Apr 15;10(8):2818-23. doi: 10.1158/1078-0432.ccr-0633-03.
• [170] GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer.Mol Cell Biol. 2003 Dec;23(23):8429-39. doi: 10.1128/MCB.23.23.8429-8439.2003.
• [171] Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility.Carcinogenesis. 2005 Dec;26(12):2046-9. doi: 10.1093/carcin/bgi168. Epub 2005 Jun 29.
• [172] A genetic variant in the gene encoding the stress70 protein chaperone family member STCH is associated with gastric cancer in the Japanese population.Biochem Biophys Res Commun. 2005 Sep 23;335(2):566-74. doi: 10.1016/j.bbrc.2005.07.110.
• [173] Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer.Cancer Sci. 2005 Nov;96(11):784-90. doi: 10.1111/j.1349-7006.2005.00113.x.
• [174] The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells.Cancer Lett. 2005 Apr 28;221(2):191-200. doi: 10.1016/j.canlet.2004.08.022.
• [175] FIGC, a novel FGF-induced ubiquitin-protein ligase in gastric cancers.FEBS Lett. 2004 Dec 3;578(1-2):21-5. doi: 10.1016/j.febslet.2004.10.071.
• [176] MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain.Int J Oncol. 2003 Jun;22(6):1369-74.
• [177] MGC29506 gene, frequently down-regulated in intestinal-type gastric cancer, encodes secreted-type protein with conserved cysteine residues.Int J Oncol. 2003 Jul;23(1):235-41.
• [178] The expression of GAGE gene can predict aggressive biologic behavior of intestinal type of stomach cancer.Hepatogastroenterology. 2004 Sep-Oct;51(59):1519-23.
• [179] Histologic and serum risk markers for noncardia early gastric cancer.Int J Cancer. 2005 Jun 20;115(3):463-9. doi: 10.1002/ijc.20852.
• [180] Roles of PLC-gamma2 and PKCalpha in TPA-induced apoptosis of gastric cancer cells.World J Gastroenterol. 2003 Nov;9(11):2413-8. doi: 10.3748/wjg.v9.i11.2413.
• [181] Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis.Exp Cell Res. 2004 Jun 10;296(2):337-46. doi: 10.1016/j.yexcr.2004.02.009.
• [182] [Differential expression of RPL6/Taxreb107 in drug resistant gastric cancer cell line SGC7901/ADR and its correlation with multiple-drug resistance].Zhonghua Zhong Liu Za Zhi. 2003 Jan;25(1):21-5.
• [183] Inactivating mutations of the Siah-1 gene in gastric cancer.Oncogene. 2004 Nov 11;23(53):8591-6. doi: 10.1038/sj.onc.1208113.
• [184] TP53BP2 locus is associated with gastric cancer susceptibility.Int J Cancer. 2005 Dec 20;117(6):957-60. doi: 10.1002/ijc.21281.
• [185] P53-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells.Oncol Rep. 2003 Sep-Oct;10(5):1265-9.
• [186] Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.Oncotarget. 2018 Sep 18;9(73):33832-33843. doi: 10.18632/oncotarget.26112. eCollection 2018 Sep 18.
• [187] Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer.Clin Cancer Res. 2012 May 15;18(10):2987-96. doi: 10.1158/1078-0432.CCR-11-2863. Epub 2012 Mar 27.
• [188] ASCL2 expression contributes to gastric tumor migration and invasion by downregulating miR223 and inducing EMT.Mol Med Rep. 2018 Oct;18(4):3751-3759. doi: 10.3892/mmr.2018.9363. Epub 2018 Aug 8.
• [189] Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer.Clin Chim Acta. 2009 Aug;406(1-2):45-51. doi: 10.1016/j.cca.2009.05.008. Epub 2009 May 19.
• [190] MiR-92a antagonized the facilitation effect of extracellular matrix protein 1 in GC metastasis through targeting its 3'UTR region.Food Chem Toxicol. 2019 Nov;133:110779. doi: 10.1016/j.fct.2019.110779. Epub 2019 Aug 28.
• [191] Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy.World J Gastroenterol. 2006 Oct 7;12(37):6032-6. doi: 10.3748/wjg.v12.i37.6032.
• [192] Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer.Cancer Lett. 2007 Jun 18;251(1):78-85. doi: 10.1016/j.canlet.2006.11.006. Epub 2006 Dec 19.
• [193] LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer.Cancer Res. 2008 Sep 1;68(17):7147-55. doi: 10.1158/0008-5472.CAN-08-0667.
• [194] Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway.Biochem Biophys Res Commun. 2006 Jul 7;345(3):1092-8. doi: 10.1016/j.bbrc.2006.04.172. Epub 2006 May 8.
• [195] Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.BMC Cancer. 2014 Oct 9;14:753. doi: 10.1186/1471-2407-14-753.
• [196] Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors.Oncogene. 2010 Mar 25;29(12):1753-62. doi: 10.1038/onc.2009.467. Epub 2010 Jan 11.
• [197] Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas.Cancer Res. 2006 Feb 1;66(3):1346-53. doi: 10.1158/0008-5472.CAN-05-3593.
• [198] Reversal of multidrug resistance of adriamycin-resistant gastric adenocarcinoma cells through the up-regulation of DARPP-32.Dig Dis Sci. 2008 Jan;53(1):101-7. doi: 10.1007/s10620-007-9829-x. Epub 2007 May 11.
• [199] Juxtaposed genes in 7q21-22 amplicon contribute for two major gastric cancer sub-Types by mutual exclusive expression.Mol Carcinog. 2017 Apr;56(4):1239-1250. doi: 10.1002/mc.22586. Epub 2016 Nov 15.
• [200] Genetic variations in the SMAD4 gene and gastric cancer susceptibility.World J Gastroenterol. 2010 Nov 28;16(44):5635-41. doi: 10.3748/wjg.v16.i44.5635.
• [201] Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis.Gastroenterology. 2009 Oct;137(4):1346-57. doi: 10.1053/j.gastro.2009.06.041. Epub 2009 Jun 21.
• [202] Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans.Gastroenterology. 2010 Dec;139(6):2005-17. doi: 10.1053/j.gastro.2010.08.043. Epub 2010 Aug 27.
• [203] Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer.Arch Pathol Lab Med. 2014 Nov;138(11):1466-73. doi: 10.5858/arpa.2013-0285-OA.
• [204] ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation.Oncogene. 2005 Dec 1;24(54):8051-60. doi: 10.1038/sj.onc.1208952.
• [205] ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.Oncogene. 2013 Jul 11;32(28):3319-28. doi: 10.1038/onc.2012.359. Epub 2012 Aug 20.
• [206] AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity.Oncogene. 2004 Sep 16;23(42):7095-103. doi: 10.1038/sj.onc.1207932.
• [207] ANKRD33 is overexpressed in gastric adenocarcinoma and predictive for poor prognosis.Biosci Biotechnol Biochem. 2019 Nov;83(11):2075-2081. doi: 10.1080/09168451.2019.1642100. Epub 2019 Jul 17.
• [208] Phenotypic variations of gastric neoplasms in familial adenomatous polyposis are associated with endoscopic status of atrophic gastritis.Dig Endosc. 2020 May;32(4):547-556. doi: 10.1111/den.13512. Epub 2019 Oct 31.
• [209] Differential expression of ARID3B in normal adult tissue and carcinomas.Gene. 2014 Jun 10;543(1):174-80. doi: 10.1016/j.gene.2014.04.007. Epub 2014 Apr 3.
• [210] Reduced expression of the insulin-induced protein 1 and p41 Arp2/3 complex genes in human gastric cancers.Int J Cancer. 2002 Jul 1;100(1):57-62. doi: 10.1002/ijc.10464.
• [211] Hath1 up-regulates gastric mucin gene expression in gastric cells.Biochem Biophys Res Commun. 2006 Jun 16;344(4):1166-71. doi: 10.1016/j.bbrc.2006.03.238. Epub 2006 Apr 21.
• [212] DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer.Gastroenterology. 2008 Jul;135(1):142-151.e3. doi: 10.1053/j.gastro.2008.03.031. Epub 2008 Mar 21.
• [213] Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol. 2004 Apr;202(4):439-45. doi: 10.1002/path.1532.
• [214] Somatic mutations of the beta-TrCP gene in gastric cancer.APMIS. 2007 Feb;115(2):127-33. doi: 10.1111/j.1600-0463.2007.apm_562.x.
• [215] Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer.Mol Cancer Res. 2007 Dec;5(12):1254-62. doi: 10.1158/1541-7786.MCR-06-0426.
• [216] Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.Int J Cancer. 2008 Apr 1;122(7):1573-84. doi: 10.1002/ijc.23166.
• [217] Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer.Int J Cancer. 2005 Jan 10;113(2):221-8. doi: 10.1002/ijc.20551.
• [218] CD81 is a candidate tumor suppressor gene in human gastric cancer.Cell Oncol (Dordr). 2013 Apr;36(2):141-53. doi: 10.1007/s13402-012-0119-z. Epub 2012 Dec 21.
• [219] Nuclear transcription factor CDX2 inhibits gastric cancercell growth and reverses epithelialtomesenchymal transition in vitro and in vivo.Mol Med Rep. 2015 Oct;12(4):5231-8. doi: 10.3892/mmr.2015.4114. Epub 2015 Jul 22.
• [220] CIAPIN1 inhibits gastric cancer cell proliferation and cell cycle progression by downregulating CyclinD1 and upregulating P27.Cancer Biol Ther. 2007 Oct;6(10):1539-45. doi: 10.4161/cbt.6.10.4684.
• [221] Underexpressed CNDP2 participates in gastric cancer growth inhibition through activating the MAPK signaling pathway.Mol Med. 2014 Mar 13;20(1):17-28. doi: 10.2119/molmed.2013.00102.
• [222] Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncol Rep. 2008 Nov;20(5):1093-7.
• [223] CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma.J Cell Physiol. 2019 Mar;234(3):2895-2904. doi: 10.1002/jcp.27106. Epub 2018 Aug 4.
• [224] Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples.Cancer Sci. 2008 Nov;99(11):2193-9. doi: 10.1111/j.1349-7006.2008.00935.x. Epub 2008 Jan 11.
• [225] Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-B signaling pathway.Mol Med. 2012 Dec 20;18(1):1402-11. doi: 10.2119/molmed.2012.00243.
• [226] Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma.Biochem Biophys Res Commun. 2003 Jul 18;307(1):52-63. doi: 10.1016/s0006-291x(03)01121-5.
• [227] Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer.J Cancer Res Clin Oncol. 2002 Jul;128(7):343-8. doi: 10.1007/s00432-002-0355-0. Epub 2002 Jun 26.
• [228] Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.Biomarkers. 2011 Feb;16(1):74-82. doi: 10.3109/1354750X.2010.533284. Epub 2010 Dec 6.
• [229] Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer.EBioMedicine. 2019 Mar;41:256-267. doi: 10.1016/j.ebiom.2019.01.066. Epub 2019 Feb 7.
• [230] Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One. 2011;6(10):e25564. doi: 10.1371/journal.pone.0025564. Epub 2011 Oct 19.
• [231] Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis.Gastroenterology. 2013 Jan;144(1):122-133.e9. doi: 10.1053/j.gastro.2012.10.002. Epub 2012 Oct 8.
• [232] Interleukin 1 Up-regulates MicroRNA 135b to Promote Inflammation-Associated Gastric Carcinogenesis in Mice.Gastroenterology. 2019 Mar;156(4):1140-1155.e4. doi: 10.1053/j.gastro.2018.11.059. Epub 2018 Nov 30.
• [233] Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.Clin Cancer Res. 2005 Apr 15;11(8):3025-31. doi: 10.1158/1078-0432.CCR-04-1605.
• [234] Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies.World J Gastroenterol. 2004 May 1;10(9):1246-9. doi: 10.3748/wjg.v10.i9.1246.
• [235] Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas.Cancer Sci. 2005 Aug;96(8):498-506. doi: 10.1111/j.1349-7006.2005.00073.x.
• [236] Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.Mol Cancer Ther. 2014 Feb;13(2):468-74. doi: 10.1158/1535-7163.MCT-13-0583-T. Epub 2014 Jan 7.
• [237] Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer.Br J Cancer. 2007 Aug 20;97(4):543-9. doi: 10.1038/sj.bjc.6603905. Epub 2007 Jul 24.
• [238] Genetic alterations of the KLF6 gene in gastric cancer.Oncogene. 2005 Jun 30;24(28):4588-90. doi: 10.1038/sj.onc.1208670.
• [239] Splice-site genetic polymorphism of the human kallikrein 12 (KLK12) gene correlates with no substantial expression of KLK12 protein having serine protease activity.Hum Mutat. 2004 Sep;24(3):273-4. doi: 10.1002/humu.9270.
• [240] Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas.Clin Biochem. 2010 Oct;43(15):1205-11. doi: 10.1016/j.clinbiochem.2010.07.016. Epub 2010 Jul 30.
• [241] Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer.Oncotarget. 2013 Sep;4(9):1461-71. doi: 10.18632/oncotarget.1219.
• [242] The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration.Biochem Biophys Res Commun. 2006 Oct 27;349(3):1032-40. doi: 10.1016/j.bbrc.2006.08.128. Epub 2006 Aug 30.
• [243] M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signaling pathways.J Cell Biochem. 2020 Mar;121(3):2330-2342. doi: 10.1002/jcb.29456. Epub 2019 Nov 6.
• [244] Expression of MTLC gene in gastric carcinoma.World J Gastroenterol. 2003 Oct;9(10):2160-3. doi: 10.3748/wjg.v9.i10.2160.
• [245] B7-H6 protein expression has no prognostic significance in human gastric carcinoma.Pathol Oncol Res. 2014 Jan;20(1):203-7. doi: 10.1007/s12253-013-9686-1. Epub 2013 Nov 16.
• [246] Inactivating mutations of the human base excision repair gene NEIL1 in gastric cancer.Carcinogenesis. 2004 Dec;25(12):2311-7. doi: 10.1093/carcin/bgh267. Epub 2004 Aug 19.
• [247] Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer.Surgery. 2007 Jan;141(1):41-50. doi: 10.1016/j.surg.2006.05.009. Epub 2006 Aug 14.
• [248] A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma.Nat Genet. 2010 Sep;42(9):764-7. doi: 10.1038/ng.649. Epub 2010 Aug 22.
• [249] Detection of frameshift mutations of RIZ in gastric cancers with microsatellite instability.World J Gastroenterol. 2004 Sep 15;10(18):2719-22. doi: 10.3748/wjg.v10.i18.2719.
• [250] Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J Gastroenterol. 2007 Nov 21;13(43):5692-8. doi: 10.3748/wjg.v13.i43.5692.
• [251] RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer.Br J Cancer. 2005 Dec 12;93(12):1395-9. doi: 10.1038/sj.bjc.6602854.
• [252] miR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cells. Tumour Biol. 2015 Apr;36(4):2393-401.
• [253] REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype.Oncogene. 2017 Jan 12;36(2):182-193. doi: 10.1038/onc.2016.187. Epub 2016 May 23.
• [254] REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells.Carcinogenesis. 2008 Jan;29(1):76-83. doi: 10.1093/carcin/bgm250. Epub 2007 Nov 16.
• [255] Genetic analysis of the DBC2 gene in gastric cancer.Acta Oncol. 2008;47(3):366-71. doi: 10.1080/02841860701644094. Epub 2007 Sep 28.
• [256] Synergistic enhancement of cancer therapy using a combination of fusion protein MG7-scFv/SEB and tumor necrosis factor alpha.Protein Pept Lett. 2013 Apr;20(4):467-72.
• [257] SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer.Cancer Genet. 2013 May;206(5):174-82. doi: 10.1016/j.cancergen.2013.04.005. Epub 2013 Jul 5.
• [258] Altered splicing pattern of TACC1 mRNA in gastric cancer.Cancer Genet Cytogenet. 2002 Nov;139(1):78-83. doi: 10.1016/s0165-4608(02)00607-6.
• [259] Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers.Anticancer Res. 2002 Nov-Dec;22(6A):3303-7.
• [260] Distinct TPEF/HPP1 gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis.Dig Liver Dis. 2008 Dec;40(12):920-6. doi: 10.1016/j.dld.2008.05.004. Epub 2008 Sep 16.
• [261] High DcR3 expression predicts stage pN2-3 in gastric cancer.Am J Clin Oncol. 2008 Feb;31(1):79-83. doi: 10.1097/COC.0b013e3180ca77ad.
• [262] Difference of p53AIP1 mRNA expression in gastric mucosa between patients with gastric cancer and chronic gastritis infected with Helicobacter pylori.J Clin Gastroenterol. 2008 Apr;42(4):351-5. doi: 10.1097/MCG.0b013e318054493e.
• [263] Identification of TRAK1 (Trafficking protein, kinesin-binding 1) as MGb2-Ag: a novel cancer biomarker.Cancer Lett. 2009 Feb 18;274(2):250-8. doi: 10.1016/j.canlet.2008.09.031. Epub 2008 Nov 4.
• [264] Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance.Med Oncol. 2014 Jul;31(7):42. doi: 10.1007/s12032-014-0042-4.
• [265] Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2.Cancer Sci. 2007 Jul;98(7):1120-7. doi: 10.1111/j.1349-7006.2007.00486.x. Epub 2007 Apr 23.
• [266] Revealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arrays.PLoS One. 2012;7(9):e44615. doi: 10.1371/journal.pone.0044615. Epub 2012 Sep 7.
• [267] The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer.J Surg Oncol. 2008 Jun 1;97(7):609-14. doi: 10.1002/jso.21046.
• [268] Functions of the AP-2 gene in activating apoptosis and inhibiting proliferation of gastric cancer cells both in vitro and in vivo.Arch Med Sci. 2017 Oct;13(6):1255-1261. doi: 10.5114/aoms.2017.71064. Epub 2017 Oct 31.
• [269] RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.Clin Cancer Res. 2009 Apr 15;15(8):2612-9. doi: 10.1158/1078-0432.CCR-08-2192. Epub 2009 Apr 7.
• [270] Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients.Dig Dis Sci. 2009 Feb;54(2):342-7. doi: 10.1007/s10620-008-0350-7. Epub 2008 Jul 5.
• [271] km23, a transforming growth factor-beta signaling component, is infrequently mutated in human colorectal and gastric cancers.Cancer Genet Cytogenet. 2007 Jun;175(2):173-4. doi: 10.1016/j.cancergencyto.2007.02.004.
• [272] The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers.Oncogene. 2008 Jul 10;27(30):4255-60. doi: 10.1038/onc.2008.62. Epub 2008 Apr 21.
• [273] Increased expression of endonuclease G in gastric and colorectal carcinomas.Tumori. 2008 May-Jun;94(3):351-5. doi: 10.1177/030089160809400311.
• [274] Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer.Br J Cancer. 2008 Dec 16;99(12):2083-7. doi: 10.1038/sj.bjc.6604760. Epub 2008 Nov 4.
• [275] Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation.J Cancer Res Clin Oncol. 2008 Mar;134(3):353-64. doi: 10.1007/s00432-007-0291-0. Epub 2007 Aug 7.
• [276] Conserved POU-binding site linked to SP1-binding site within FZD5 promoter: Transcriptional mechanisms of FZD5 in undifferentiated human ES cells, fetal liver/spleen, adult colon, pancreatic islet, and diffuse-type gastric cancer.Int J Oncol. 2007 Mar;30(3):751-5.
• [277] GKN1 expression in gastric cancer cells is negatively regulated by miR-544a.Biochimie. 2019 Dec;167:42-48. doi: 10.1016/j.biochi.2019.09.005. Epub 2019 Sep 8.
• [278] Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.BMC Cancer. 2016 Jan 22;16:35. doi: 10.1186/s12885-016-2058-y.
• [279] Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt.J Gastroenterol. 2016 Mar;51(3):230-40. doi: 10.1007/s00535-015-1101-0. Epub 2015 Jul 23.
• [280] IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells.Int J Cancer. 2008 Mar 1;122(5):1040-6. doi: 10.1002/ijc.23181.
• [281] The implication of N-acetylglucosaminyltransferase V expression in gastric cancer.Pathobiology. 2008;75(5):288-94. doi: 10.1159/000151709. Epub 2008 Oct 15.
• [282] Risk Factors for Metachronous Gastric Neoplasms in Patients Who Underwent Endoscopic Resection of a Gastric Neoplasm.Gut Liver. 2016 Mar;10(2):228-36. doi: 10.5009/gnl14472.
• [283] Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.Gastroenterology. 2009 Feb;136(2):640-51.e1. doi: 10.1053/j.gastro.2008.10.050. Epub 2008 Oct 29.
• [284] Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells.Apoptosis. 2006 Jun;11(6):993-1001. doi: 10.1007/s10495-006-6714-6.
• [285] Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance.World J Gastroenterol. 2008 Jan 14;14(2):292-7. doi: 10.3748/wjg.14.292.
• [286] Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells.Int J Cancer. 2006 Apr 15;118(8):1922-9. doi: 10.1002/ijc.21575.
• [287] Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer.Cancer Res. 2008 Jun 15;68(12):4623-30. doi: 10.1158/0008-5472.CAN-07-5870.
• [288] RhoC is essential for the metastasis of gastric cancer.J Mol Med (Berl). 2007 Oct;85(10):1149-56. doi: 10.1007/s00109-007-0217-y. Epub 2007 Jun 5.
• [289] RhoE enhances multidrug resistance of gastric cancer cells by suppressing Bax.Biochem Biophys Res Commun. 2009 Feb 6;379(2):212-6. doi: 10.1016/j.bbrc.2008.12.044. Epub 2008 Dec 25.
• [290] Reprimo as a potential biomarker for early detection in gastric cancer.Clin Cancer Res. 2008 Oct 1;14(19):6264-9. doi: 10.1158/1078-0432.CCR-07-4522.
• [291] In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity.Clin Cancer Res. 2006 Aug 15;12(16):4965-73. doi: 10.1158/1078-0432.CCR-05-2316.
• [292] Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer.Int J Cancer. 2009 Feb 1;124(3):739-44. doi: 10.1002/ijc.23960.
• [293] Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers.Lab Invest. 2008 Feb;88(2):153-60. doi: 10.1038/labinvest.3700706. Epub 2007 Dec 3.